FDA Grants Fast Track designation to IVS-3001, Invectys...
FDA Grants Fast Track designation to IVS-3001, a CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma Houston, TX, USA, July 31, 2023 – Invectys,…
Read more
FDA Grants Fast Track designation to IVS-3001, a CAR-T Cell Therapy in the Treatment of Renal Cell Carcinoma Houston, TX, USA, July 31, 2023 – Invectys,…
Invectys Announces Initiation of Phase 1/2a Clinical Trial in Solid Tumors and Change in Leadership Houston, TX, USA, July 13, 2023 – Invectys, Inc., a clinical-stage…
Invectys awarded “2023 Best Translational Development” by the MATWIN international Board Houston, TX, USA, May 26, 2023 – Invectys Inc., a clinical-stage…
Monoclonal antibodies targeting checkpoint inhibitors are hugely important immunotherapy molecules for the treatment cancers…
The telomerase enzyme functions as part of a large ensemble of proteins and RNA called the telomerase ribonucleoprotein complex.…
The main product of Invectys is a DNA vaccine targeting Telomerase…